Background The identification of biomarkers to select pts most likely to benefit from immunotherapy is still an unmet clinical need. The Meet-URO 18 study is a multicenter study assessing the I-TME in mRCC pts treated with ≥2nd line nivolumab divided according to clinical benefit in responders versus non-responders (progression-free survival ≥ 12 vs ≤ 3 months, respectively). Methods Histology and grading assessment and digital multitarget IHC analyses were performed on the I-TME of the primary tumor or the metastases assessing T-lineage (CD3, CD4, CD8, CD8/CD4 ratio, peritumoral T cells), macrophages (CD68) and granulocytes (CD15). Phosphorylated mTOR (ph-mTOR), CD56 and PD-L1 (SP263) expression on tumor cells were also assessed. Receiver operating curves (ROC) based on responses were used to identify cut-off values of the I-TME parameters. Differences between the two pts groups were reported as odds-ratios (OR) with the 95% CI and considered statistically significant with a p value of < 0.05. Results Overall, 116 tumor tissue samples (59% primary tumors, 41% metastases) were evaluated. Responders (N = 55) presented lower expression of CD4 and higher levels of ph-mTOR and CD56 compared to non responders. Responders showed also a tendency towards higher CD3 expression (≥40: 73% vs 56%, p=0.059) and CD8/CD4 ratio (median 1.74 vs 1.20, p=0.084). Non responders (N = 61) presented with clear cell histology (CCRCC) and higher grading. Statistically significant results are summarized in the table.

1476P Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study / Rebuzzi, S. E.; Rescigno, P.; Signori, A.; Brunelli, M.; Galuppini, F.; Vellone, V. G.; Gaggero, G.; Maruzzo, M.; Milella, M.; Vignani, F.; Cavo, A.; Basso, U.; Catalano, F.; Murianni, V.; Cremante, M.; Damassi, A.; Llaja Obispo, M. A.; Banna, G. L.; Buti, S.; Fornarini, G.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 33:(2022), pp. S1221-S1222. [10.1016/j.annonc.2022.07.1579]

1476P Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study

Buti, S.;
2022-01-01

Abstract

Background The identification of biomarkers to select pts most likely to benefit from immunotherapy is still an unmet clinical need. The Meet-URO 18 study is a multicenter study assessing the I-TME in mRCC pts treated with ≥2nd line nivolumab divided according to clinical benefit in responders versus non-responders (progression-free survival ≥ 12 vs ≤ 3 months, respectively). Methods Histology and grading assessment and digital multitarget IHC analyses were performed on the I-TME of the primary tumor or the metastases assessing T-lineage (CD3, CD4, CD8, CD8/CD4 ratio, peritumoral T cells), macrophages (CD68) and granulocytes (CD15). Phosphorylated mTOR (ph-mTOR), CD56 and PD-L1 (SP263) expression on tumor cells were also assessed. Receiver operating curves (ROC) based on responses were used to identify cut-off values of the I-TME parameters. Differences between the two pts groups were reported as odds-ratios (OR) with the 95% CI and considered statistically significant with a p value of < 0.05. Results Overall, 116 tumor tissue samples (59% primary tumors, 41% metastases) were evaluated. Responders (N = 55) presented lower expression of CD4 and higher levels of ph-mTOR and CD56 compared to non responders. Responders showed also a tendency towards higher CD3 expression (≥40: 73% vs 56%, p=0.059) and CD8/CD4 ratio (median 1.74 vs 1.20, p=0.084). Non responders (N = 61) presented with clear cell histology (CCRCC) and higher grading. Statistically significant results are summarized in the table.
1476P Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study / Rebuzzi, S. E.; Rescigno, P.; Signori, A.; Brunelli, M.; Galuppini, F.; Vellone, V. G.; Gaggero, G.; Maruzzo, M.; Milella, M.; Vignani, F.; Cavo, A.; Basso, U.; Catalano, F.; Murianni, V.; Cremante, M.; Damassi, A.; Llaja Obispo, M. A.; Banna, G. L.; Buti, S.; Fornarini, G.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 33:(2022), pp. S1221-S1222. [10.1016/j.annonc.2022.07.1579]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2930373
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact